US EditionBayer’s Asundexian Reduced Recurrent Ischemic Stroke in OCEANIC-STROKE
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.4 Articles
4 Articles
elcorreoweb.es
sport.esA research drug could open a new way in secondary stroke prevention, one of the leading causes of death and disability in the world. The results of the international phase III OCEANIC-STROKE trial indicate that the experimental asundexian anticoagulant developed by Bayer pharmaceuticals reduced the risk of a new ischemic stroke by 26% in patients who had already had a stroke, without increasing serious bleeding complications.
Endovascular Today
Cardiac Interventions TodayBayer’s Asundexian Reduced Recurrent Ischemic Stroke in OCEANIC-STROKE
February 19, 2026—Bayer recently reported that its oral factor XIa inhibitor asundexian reduced the risk of recurrent ischemic stroke in patients after noncardioembolic ischemic stroke or high-risk transient ischemic attack (TIA), meeting the primary efficacy endpoint of the phase 3 OCEANIC-STROKE trial, according to the company’s announcement. In the randomized trial, asundexian 50 mg once daily on top of antiplatelet therapy was associated wit…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium